RTI Surgical (RTIX) : Zacks Investment Research ranks RTI Surgical (RTIX) as 4, which is a Sell recommendation. A total of 2 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 2 research analysts is 3, which indicates as a Hold.
Shares of RTI Surgical Inc. appreciated by 3.1% during the last five trading days but lost 14.4% on a 4-week basis. RTI Surgical Inc. has dropped 14.4% during the last 3-month period . Year-to-Date the stock performance stands at -16.12%. RTI Surgical (NASDAQ:RTIX): stock turned positive on Tuesday. Though the stock opened at $3.33, the bulls momentum made the stock top out at $3.34 level for the day. The stock recorded a low of $3.293 and closed the trading day at $3.33, in the green by 0.60%. The total traded volume for the day was 85,356. The stock had closed at $3.31 in the previous days trading.
RTI Surgical, Inc. produces orthopedic and other surgical implants that repair and promote the natural healing of human bone and other human tissues and improve surgical outcomes. The Company uses natural tissues, metals and synthetics process to produce its products. The Company processes donated human musculoskeletal and other tissue, including bone, cartilage, tendon, ligament, fascia lata, pericardium, sclera and dermal tissue, and bovine and porcine animal tissue in producing allograft and xenograft implants utilizing BIOCLEANSE, TUTOPLAST and CANCELLE SP sterilization processes and manufacture metal and synthetic implants for distribution to hospitals and surgeons. The Companys business has six categories: spine, sports medicine, ortho fixation, bone graft substitutes and general orthopedic (BGS and general orthopedic), surgical specialties and dental. The Company distributes its implants and services in all 50 states and in over 45 countries worldwide.